"10.1371_journal.pone.0114393","plos one","2014-12-03T00:00:00Z","Rian M Nijmeijer; Frank G Schaap; Alexander J J Smits; Andreas E Kremer; Louis M A Akkermans; Alfons B A Kroese; Ger T Rijkers; Marguerite E I Schipper; Andr√© Verheem; Cisca Wijmenga; Hein G Gooszen; Karel J van Erpecum","Department of Surgery, University Medical Center Utrecht, Utrecht, the Netherlands; Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, Amsterdam, the Netherlands; Department of General Surgery, Maastricht University, Maastricht, The Netherlands; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Medicine 1, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany; Neurotoxicology Research Group, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands; Department of Operating Rooms, University Medical Center St. Radboud, Nijmegen, the Netherlands; Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, the Netherlands; Department of Genetics, University Medical Centrum Groningen, University of Groningen, Groningen, the Netherlands; Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, the Netherlands","Performed the experiments: RMN FGS AEK ABAK AV. Analyzed the data: RMN FGS AJJS ABAK MEIS GTR KJvE. Contributed reagents/materials/analysis tools: FGS ABAK GTR MEIS CW KJvE. Conceived and designed the experiments: RMN FGS LMAA KJvE. Wrote the paper: RMN FGS KJvE. Data acquisition: RMN FGS AJJS AEK ABAK MEIS AV. Analysis and interpretation of data: RMN FGS ABAK GTR KJvE. Critical revision of manuscript: AJJS AEK LMAA ABAK GTR MEIS AV CW HGG. Supervision of study: CW HGG KJvE. Approved the final draft submitted: RMN FGS AJJS AEK LMAA ABAK GTR MEIS AV CW HGG KJvE.","The authors have read the journals policy and have the following conflicts: KJvE has participated in a clinical study on the effects of the FXR agonist INT747 (Obeticholic acid) in patients with primary biliary cirrhosis. The other authors have declared that no competing interests exist. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","12","Rian M Nijmeijer","RMN",12,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA
